Raymond James Cuts Danaher (NYSE:DHR) Price Target to $300.00

Danaher (NYSE:DHR) had its price target cut by Raymond James from $310.00 to $300.00 in a report released on Wednesday, Benzinga reports. They currently have an outperform rating on the conglomerate’s stock.

A number of other analysts have also commented on the company. Barclays decreased their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday. KeyCorp boosted their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday. Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. The Goldman Sachs Group boosted their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Finally, Leerink Partners boosted their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Stock Performance

Shares of Danaher stock opened at $245.39 on Wednesday. Danaher has a one year low of $182.09 and a one year high of $281.70. The firm has a market capitalization of $181.76 billion, a price-to-earnings ratio of 41.59, a PEG ratio of 4.49 and a beta of 0.83. The business has a 50-day simple moving average of $269.52 and a 200 day simple moving average of $260.42. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the company posted $2.02 EPS. The firm’s revenue was up 3.1% compared to the same quarter last year. On average, research analysts anticipate that Danaher will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s payout ratio is 18.31%.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Linda Filler sold 3,928 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the sale, the director now owns 41,149 shares in the company, valued at approximately $11,501,145.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,059 shares of company stock worth $8,400,897. Insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

Several institutional investors have recently made changes to their positions in DHR. Vanguard Group Inc. lifted its position in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after acquiring an additional 4,163,657 shares in the last quarter. Swedbank AB bought a new stake in Danaher during the first quarter valued at $676,545,000. TD Asset Management Inc grew its position in Danaher by 99.0% during the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after buying an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after acquiring an additional 563,546 shares during the last quarter. Finally, International Assets Investment Management LLC raised its holdings in shares of Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.